These findings highlight the potential therapeutic significance of selectively targeting the p38-MAPK and NF-κB pathways in modulating miR-125b-5p function and its downstream effector MMP-2 in lung cancer progression. This evidence concerns the gene MMP2 and lung carcinoma.